A Prospective, Open Label, Multicenter Trial for Evaluating the Efficacy of Treating and Managing Wounds in Elderly Population in Specialized Nursing Facilities Using RedDress Wound Care System (RD1)
Phase: NA
Conditions: Diabetic Foot Ulcer, Pressure Ulcer, Venous Leg Ulcer, Trauma Injury, Skin Tear, Chronic Ulcer
Sponsor: RedDress Ltd.

 
A PROSPECTIVE, OPEN LABEL, MULTICENTER TRIAL FOR 
EVALUATING THE EFFICACY OF TREATING AND MANAGING WOUNDS 
IN ELDERLY POPULATION IN SPECIALIZED NURSING FACILITIES 
USING  REDDRESS WOUND CARE SYSTEM (RD1)   
 
NCT04577183      
 
 
AUGUST 13, 2018 
      

        RD004 Rev 1.1, dated 13 August 2018                                             Page 1 of 45 
Clinical Protocol  - RD004 Confidential 
 
 
 
 
 
 
 
 
 
 
 
 
 
Authorization 
 
Name 
Title 
Signature 
Date 
Written By: 
Sharon Sirota 
CTL 
 
 
Approved 
By: 
Alon Kushnir 
CEO 
 
 
Revision History 
Rev. 
No. 
p.No & 
section 
Description 
Date 
1 
 
NEW  
19 Jun 2018 
(Approved by 
FDA on 27 Jun 
2018  
2 
14, 2.1.16 
Removed: Dialysis removed from exclusion criteria 
13 Aug 2018 
8, 1.3-Subject 
population 
Added: Patient that require Legally Authorized 
Representative (LAR) 
Appendix 2: 
RD1 
Application 
Protocol, 
RD1 
Preparation  
Added: Two  FDA cleared 8.5ml vacuum tubes with 
ACDA  Solution. Added throughout the appendix    
 
Appendix 2: 
RD1 
Application 
Protocol, P.27 
Table 1 
Changed: RD1 diameter units changed from cm2  to cm 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 2 of 45 
Clinical Protocol  - RD004 Confidential 
 
 
  
 
 
 
RedDress Wound Care System 
Protocol RD004 
 
Dated 19 June 2018 
  
A Prospective, Open Label, Multicenter trial for evaluating the Efficacy of Treating and 
Managing Wounds in Elderly Population in Specialized Nursing Facilities Using  RedDress 
Wound Care System (RD1)   
 
 
 
Principal Investigator: Dr.Bryan Doner, DO  
Tel: 412-496-6365 
Fax: 724-543-8802 
Email: drdoner@dandpmedicalgroup.com 
 
 
Sponsor: RedDress LTD.  
Contact Person: Alon Kushnir 
Tel: (972) 547800252 
alon@reddress.co.il 
 
CONFIDENTIAL 
 
The information contained herein is confidential and proprietary. 
It is intended for the use of RedDress ltd, ACES Group clinical investigations, 
Institutional review committees, and others directly involved in this clinical 
investigation.  No unpublished information presented in this document may be 
reproduced or referred to in publications or public presentations without 
the expressed written consent of RedDress ltd. 
 
 
 
 
 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 3 of 45 
Clinical Protocol  - RD004 Confidential 
 
 
 
 
 
 
 
 
 
PROTOCOL APPROVAL FORM 
 
 
 
 
Study Number: 
RD-004 
 
 
Study Name: A Prospective, Open Label, Multicenter trial for evaluating the Efficacy of 
Treating and Managing Wounds in Elderly Population in Specialized 
Nursing Facilities Using RedDress Wound Care System (RD1) 
 
 
This Protocol has been reviewed and approved by the following: 
 
________________________________________ 
 
____________________________ 
Dr. Bryan Doner, DO                                                                      Date 
Principal Investigator                                                                                                                                                       
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 4 of 45 
Clinical Protocol  - RD004 Confidential 
Contents 
INTRODUCTION……….. ................................................................................................................................... 6 
1. OVERVIEW……….. .................................................................................................................................... 7 
1.1. 
Study Objectives ............................................................................................................................. 7 
1.2. 
Study Design ................................................................................................................................... 8 
1.3. 
Subject Population ......................................................................................................................... 8 
 
1.3.1 Patient that require Legally Authorized Representative (LAR) 
1.4. 
Study Duration ................................................................................................................................ 9 
1.5. 
Treatment Regimen ........................................................................................................................ 9 
1.6. 
Assessment ..................................................................................................................................... 9 
2. SELECTION CRITERIA ............................................................................................................................. 13 
2.1. 
Inclusion Criteria ........................................................................................................................... 13 
2.2. 
Exclusion Criteria .......................................................................................................................... 14 
2.3. 
Investigator and Site Selection ..................................................................................................... 14 
3. DIAGNOSTIC EVALUATIONS .................................................................................................................. 15 
3.1. 
Laboratory Tests ........................................................................................................................... 15 
4. STOPPING RULES .................................................................................................................................. 15 
4.1. 
Individuals ..................................................................................................................................... 15 
4.3. 
Study ............................................................................................................................................. 15 
5. LONG TERM FOLLOW-UP ..................................................................................................................... 16 
5.1. 
General ......................................................................................................................................... 16 
6. MISSED VISITS…. ................................................................................................................................... 16 
7. ADVERSE EVENTS .................................................................................................................................. 16 
7.1. 
Serious Adverse Events ................................................................................................................ 16 
7.2. 
Device-related Adverse Events ..................................................................................................... 17 
7.3. 
Adverse Events ............................................................................................................................. 17 
7.4. 
Subject Referral to another Facility .............................................................................................. 18 
8. PREMATURE WITHDRAWAL OF SUBJECTS ........................................................................................... 18 
9. LOST TO FOLLOW-UP ............................................................................................................................ 18 
10. SUBJECT COMPLIANCE ......................................................................................................................... 19 
11. STUDY MONITORING ............................................................................................................................ 19 
11.1. Study Records/Source Document Inspection ............................................................................... 19 
11.2. Monitors ....................................................................................................................................... 19 
11.3. Monitoring Plan ............................................................................................................................ 19 
12. RECORDS HANDLING AND KEEPING ..................................................................................................... 21 
12.1. Source Documents ....................................................................................................................... 21 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 5 of 45 
Clinical Protocol  - RD004 Confidential 
12.2. Data Collection Method ............................................................................................................... 22 
13. DATA ANALYSIS..................................................................................................................................... 22 
13.1. Study Population and Sample size................................................................................................ 22 
13.2. Statistical Analyses ....................................................................................................................... 22 
13.2.1. Primary Endpoint ......................................................................................................................... 22 
13.2.2. Secondary Endpoints ................................................................................................................... 22 
14. REGULATORY OBLIGATIONS ................................................................................................................. 23 
14.1 Sponsor’s Obligations ................................................................................................................... 23 
14.2 Investigator’s Obligations ............................................................................................................. 23 
15. STUDY COMPLETION ............................................................................................................................ 24 
16. PROTOCOL DEVIATIONS AND EXCEPTIONS .......................................................................................... 24 
17. ETHICAL STUDY CONDUCT ................................................................................................................... 25 
18. CONFIDENTIALITY/PUBLICATION OF STUDY RESULTS.......................................................................... 25 
APPENDIX 1   - INFORMED CONSENT FORM ................................................................................................. 26 
APPENDIX 2- RD1™ APPLICATION PROTOCOL ............................................................................................ 27 
APPENDIX 3- PHOTOGRAPHIC TECHNIQUE ................................................................................................ 32 
APPENDIX 4- WOUND MEASUREMENT ...................................................................................................... 33 
APPENDIX 5- IMAGING CHARTER ................................................................................................................ 34 
APPENDIX 6- TRAINING AND STANDARDIZATION OF CARE AT CENTERS ................................................... 35 
APPENDIX 7- SCHEDULE OF EVENTS ........................................................................................................... 36 
APPENDIX 8  - DEBRIDEMENT ....................................................................................................................... 37 
APPENDIX 9- ULCER GRADING SYSTEM ...................................................................................................... 38 
APPENDIX 10- NEUROPATHIC ASSESSMENT ............................................................................................... 40 
APPENDIX 11- INFECTION ASSESSMENT ..................................................................................................... 41 
APPENDIX 12- MOISTURE CONTROL ASSESSMENT .................................................................................... 42 
APPENDIX 13- OFFLOADING DEVICE INSTRUCTIONS .................................................................................. 43 
APPENDIX 14- HYGROGEL STANDARD CARE ............................................................................................... 44 
APPENDIX 15- INVESIGATOR SUBJECTIVE ULCER PAIN ASSESSMENT ........................................................ 45 
APPENDIX 16- PROCEDURE COST AND STAFF LABOR ASSESSMENTS......................................................... 46 
INVESTIGATOR AGREEMENT FOR TRIAL PROTOCOL .................................................................................. 47 
REFERENCES (cited and selected) ............................................................................................................... 48 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 6 of 45 
Clinical Protocol  - RD004 Confidential 
 
 
INTRODUCTION 
 
 
In order for a wound to heal multiple processes must work in concert. The tissue must receive 
adequate arterial flow, the bacterial burden must be controlled, the environment must have a 
proper moisture balance, and negative mechanical forces must be eliminated. Wounds can vary in 
size and depth; wounds can be clean with a predominance of healthy granulation tissue or have 
nonviable or necrotic material present, which inhibits healing.   
 
The acute wound which is common, heals in a predictable and orderly fashion. Healing begins with 
initiation of the clotting cascade, which in turn results in the proteolytic cleavage of fibrinogen by 
the enzyme thrombin, forming an insoluble blood clot. The blood clot holds damaged tissues 
together and provides the provisional matrix required for the natural healing process. In addition 
the outer layer of the clot dries out and creates a degradable crust formed from erythrocytes and 
other blood components. This tough shell protects the wound from contact with environmental 
hazards, reduces pain, protects the wound from bacterial contamination, and enables a moist 
wound environment under it, allowing the repair process to take place unhindered. The clot is a 
provisional extracellular matrix (ECM), which harbors cytokines and growth factors released by the 
degranulation of activated platelets and other cells within the clot. The acute wound beneath the 
clot heals and the remaining dry crust is shed exposing the reconstructed skin.  
 
Chronic wounds such as diabetic ulcers, pressure ulcers and venous ulcers, on the other hand do 
not heal or heal slowly because an underlying defect (e.g. diabetes mellitus, continued pressure that 
impedes local blood flow and vascular problems.) arrests progress through the phases of wound 
healing. Most commonly chronic wounds stall in the inflammatory phase of wound healing 
characterized by the presence of non-viable tissue, excessive bacterial burden, and the presence of 
increased inflammatory cytokines.  
 
With aging comes a 20% loss in dermal thickness, making the skin of many elderly adults almost 
transparent in appearance. The subcutaneous fatty layer also becomes thinner, especially on the 
face, neck, back of the hands, and shins. If traumatized, these areas will absorb more energy than 
other parts of the body because they lack cushioning fatty subcutaneous tissue; thus, they are at 
increased risk for an injury such as a skin tear. The skin has less resilience – sufficient force exerted 
against the skin will result in a tearing-type injury. Once a skin tear is present in the elderly, the 
slower rate of epidermal cell turnover prolongs healing time. Alterations in collagen and protein 
synthesis also may contribute to delayed skin tear healing. In addition, the skin’s microcirculation 
collapses, increasing risk of bruising and reducing blood supply to the skin (the latter can prolong 
healing time if a break in the skin occurs). Because of the decreased immune response of the 
geriatric patient, skin tears have a higher risk of becoming infected than in the non-geriatric patient 
 
The formation of a whole blood clot occurs through a cascade of events. Two pathways lead to the 
formation of the final blood clot: the intrinsic and extrinsic pathways. Although they are initiated by 
different distinct mechanisms, the two converge on a common pathway leading to the same fibrin 
clot formation. The clot formation on an acute wound is through the extrinsic pathway while the in 
vitro clot formation is through the intrinsic pathway. 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 7 of 45 
Clinical Protocol  - RD004 Confidential 
A blood clot is the body’s natural and optimal provisional wound matrix. As described above, it 
protects the wound and serves as a provisional matrix into which cells can migrate. The use of the 
RD1 as a provisional matrix in the management of chronic wounds recreates the natural healing 
process. Moreover, the function of a blood clot as a provisional matrix has been validated and 
reported 
extensively 
in 
literature 
and 
in 
2 
clinical 
studies 
conducted 
with 
the  
RD1. There are several commercial available matrix or scaffold products. However, all of these 
products are derived from foreign material: animal tissue or human donor skin. An autologous blood 
clot matrix should have no immunologic rejection or risks associated with the use of animal 
products.  
 
The RD1 is created by drawing the patient’s blood with the use of citrate anticoagulant. The 
anticoagulant allows the clot to form later in a controlled fashion—citrate is a widely used 
anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation 
is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes 
the shape of the tray containing it, and can then be applied to the wound, and then covered with 
primary and secondary dressings.   
   
The use of the citrate anticoagulant is essential to the process. Withdrawing blood without the use 
of an anticoagulant would immediately initiate the coagulation cascade and within minutes a whole 
blood clot would form. Citrate, which is widely used in the blood banking industry, prevents clotting 
by binding calcium ions. Clotting can be re-initiated in vitro by adding the calcium ions to the citrated 
blood. The clotting time can be further accelerated by mixing the blood with a contact surface such 
as kaolin (insoluble aluminum silicate).  
 
The investigational product, the RD1 kit, was designed to enable a care provider to create an in vitro 
blood clot from the patient’s own blood at the point of care, in a safe and effective manner. The 
RD1 kit involves currently accepted medical procedures of halting the coagulation process and re-
initiating the natural occurring process. 
 
The proposed protocol (RD004) should be sufficient to determine the safety of RD1 in wounds of 
various etiology, such as Diabetic foot ulcers, pressure ulcer, venous ulcers and skin tears. This takes 
into account the suppositions that the proposed product is natural in origin (i.e., not synthetic), is 
not derived from animals but is autologous, and that it attempts to mimic the body’s own healing 
mechanisms of replacing missing Extra Cellular Matrix (ECM) with a fibrin-based matrix, a defect 
which exists in the local areas of chronic ulcers. Furthermore the RD1 safety was validated in 2 
clinical studies of 30 patients with wounds of various etiologies. 
 
 
 
 
1. 
OVERVIEW 
 
1.1. Study Objectives 
 
Primary Objective 
The primary objective of this protocol is: 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 8 of 45 
Clinical Protocol  - RD004 Confidential 
1. Efficacy- The performance of RD1 in terms of wound progress towards closure in 
wounds deemed suitable for treatment with RD1 
 
Secondary Objectives: 
Secondary objectives of the trial are:  
 
1. Safety - Determine complication rates for all adverse events compromising serious 
adverse events, adverse events (AEs), and device-related adverse events (DRAEs); 
AEs include any lack of venous access events 
2. Efficacy - Assess the incidence of complete wound closure at 16 weeks for wounds 
treated with RD1 (defined as skin re-epithelialization without drainage or dressing 
requirements). 
3. Efficacy - Assess the wound Percent Area Reduction (PAR) 
4. Efficacy- Assess the optimal duration between applications of RD1 per wound 
parameter  
5. Efficacy- Assess the need of design and procedure improvements of the RD1 for 
specialized nursing facilities (SNF) 
6. Sub Group Analysis – asses the safety and efficacy per wound etiology   
7. Asses the cost of RD1 procedure in SNF compared to cost of treatment before RD1 
8. Assess wound pain compared to wound pain during treatment before RD1 
9. Assess medical staff wound related weekly labor of wound treatment before and 
during RD1.  
 
 
1.2. Study Design 
 
The study is a prospective, single arm, multicenter efficacy study, consisting of 60 subjects 
who will complete the study (note: if any patients are lost to follow-up or withdrawn, 
enrollment will increase to compensate for loss of these subjects). The subjects will receive 
up to 16 RD1 applications. In case of complete healing, subject will be called for one 
confirmatory visit two weeks later or before discharge from the SNF (the earlier of the two). 
Subject data will be kept in each site’s records. 
All diabetic subjects' glycemic management will be performed by a qualified physician. All 
subjects will have wound care specialist or wound surgeon or dermatologist involved in their 
wound care 
 
1.3. Subject Population 
 
Up to 120 (or more) subjects will be enrolled at 2 SNF in the US in 2 phases: Phase I- 40 
subjects and phase II- 80 subjects). Subjects will be older than 18 years with wounds deemed 
suitable for treatment with RD1.  
 
1.3.1. 
Patient that require Legally Authorized Representative (LAR) 
The patient population that will be enrolled to the study includes patients that require LAR 
signature. The rational for inclusion of this population is that the RD1 is an FDA cleared 
product, that demonstrated significant chronic ulcers healing rates, much superior to known 
standard of care. In the nursing home, many of patients with chronic ulcers are those that 
require LAR. By not including those patients in the RD1 study, we are depriving them from 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 9 of 45 
Clinical Protocol  - RD004 Confidential 
superior treatment and with the prospect of healing their ulcers and we are discriminating 
them from those patients that do not require LAR. The RD1 was determined by FDA to be a 
safe product and will be used in the study according to the FDA cleared intended use only. 
 
Enrollment process of patients that require LAR will be according to the local regulations and 
enrollment procedure per site will be submitted to the IRB in advance including specific 
requirements in the ICF and the consenting process. 
 
 
1.4. Study Duration 
 
The study is expected to last 12 to 24 months. 
 
The study per each subject will continue for up to 16 weeks of RD1 treatment (not including 
up to 2-week screening period (± 2 days)), Any wounds that are considered initially healed 
within the 16-week period will require a confirmatory visit two weeks after healing of before 
discharge from the SNF (the earlier of the two) to assess durability of wound closure. 
 
Patients will be treated with RD1 every 7 days (±3 days), investigator can prolong the duration 
between treatments based on medical decision. Total treatment duration is up to 16 weeks 
or until complete healing.  
 
1.5. Treatment Regimen 
 
Ethics/Institutional Review Board (IRB/EC) committee approved consent is obtained prior to 
subject participation. The patients will be screened to determine if they meet the inclusion 
and exclusion criteria. The screening period lasts for up to 14 days ± 2 days. The target ulcer 
will be treated with RD1. The RD1 clot is created from the subject’s blood in accordance with 
the procedure described in the RD1 Application Protocol (Appendix 2) and according to 
accepted precautions guidelines. Patients will be treated with RD1 every 7 days (±3 days), 
investigator can prolong the duration between treatments based on medical decision. Total 
treatment duration is up to 16 weeks or until complete healing. The RD1 should be anchored 
using steri-strips then covered with a primary non-adherent dressing such as Mepitel and then 
covered using a secondary dressing based on type of wound and amount of exudate.  
 
 
1.6. Assessment 
 
1.6.1 
Screening Phase:  
  
1.6.1.1 
Written informed consent.  
 
Informed consent will be obtained by the principal investigator or 
his or her designee prior to any study-related procedures. When 
the subject or his/ her legal authorized representative is agreeable 
to participation in the clinical trial, he/she must understand, sign 
and date the IRB/EC–approved Informed Consent Document (see 
sample in Appendix 1), which describes the study and potential 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 10 of 45 
Clinical Protocol  - RD004 Confidential 
discomforts, risks, and benefits of participating. One copy of the 
consent form will be provided to the subject and one copy will be 
maintained with the subject's medical record.   
1.6.1.2 
Execution of inclusion and exclusion criteria. 
1.6.1.3 
Complete medical history and physical examination. 
1.6.1.4 
Collection of patient demographics. 
1.6.1.5 
Complete ulcer history. 
1.6.1.6 
Wound photography before cleansing/ debridement. See 
Appendices 3-4.  
1.6.1.7 
Wound cleansing 
1.6.1.8 
Wound debridement, if required (Debridement procedures are 
described in Appendix 9). 
1.6.1.9 
Wound measurement via digital photography. See Appendices 3-5. 
1.6.1.10 Wound depth measurement by accepted method. Unit of   
measurement is millimeters 
1.6.1.11 Wound 
photography 
after 
cleansing/ 
debridement. 
See 
Appendices 3-4.  
1.6.1.12 Classification and grading of study wound (if applicable). 
1.6.1.13 Neuropathic assessment (for foot ulcers only). 
1.6.1.14 Review of ulcer and blood related medications taken by the subject 
including herbal medications. 
1.6.1.15 Pregnancy test (urine) for female subjects of child-bearing 
potential. 
1.6.1.16 Assessment for infection of the target ulceration. 
1.6.1.17 Assessment of moisture control, when relevant. 
1.6.1.18 Assessment of offloading, when relevant. 
1.6.1.19 Vascular perfusion assessments will be conducted to assess 
adequate perfusion of the lower extremities using Ankle-Brachial 
Index (ABI), when relevant. ABI will be determined on the affected 
side (i.e., the side of the body on which the study ulcer resides) 
according to standard procedure/protocol at the study site.  
1.6.1.20 Laboratory. Patients who have had labs drawn within 30 days prior 
to screening do not require a repeat draw. Otherwise complete 
blood count, PT, PTT, and HbA1c will be obtained. 
1.6.1.21 X-Ray of the study ulcer will be performed in cases of suspected 
osteomyelitis. 
If the X-Ray is inconclusive regarding osteomyelitis, further 
investigation can be undertaken at the discretion of principal 
investigator. As stated below in the exclusion criteria, patients with 
underlying osteomyelitis will be excluded.  
1.6.1.22 During the screening period the wounds will be treated weekly with 
standard of care treatment . 
1.6.1.23 Investigator subjective wound pain assessment (appendix XX)    
1.6.1.24 Medical staff wound related weekly labor assessment for the week 
prior to initiation of the screening (appendix XX) (optional per 
sponsor instruction)  
1.6.1.25 Wound  treatment cost assessment for the period prior to initiation 
of screening (at least weekly cost, preferably monthly cost, if 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 11 of 45 
Clinical Protocol  - RD004 Confidential 
possible- cost since start of wound treatment)- )optional per 
sponsor instruction). 
 
 
   
1.6.2 
Treatment Phase Initial (Day 0):  
 
1.6.1.1 
Adverse event assessment. 
1.6.1.2 
Ulcer and blood related concomitant medication review. 
1.6.1.3 
Investigator subjective wound pain assessment   
1.6.2.1 
Photography before and after cleansing and debridement (if 
applicable) 
1.6.2.2 
Wound measurement by photography. Two measurements- 
before and after cleansing and debridement.  
1.6.2.3 
 Wound depth measurement by accepted method. Unit of   
measurement is millimeters. Two measurements- before and after 
cleansing and debridement  
1.6.2.4 
Ulcer cleansing  
1.6.2.5 
Ulcer debridement as needed 
1.6.2.6 
Application Regimen: as per the investigators Brochure. Up to 3 
RD1 dressings can be applied on each wound on each visit, 
according to wound size and investigator decision of subject health.  
The RD1 will be removed or applied only by the research staff. 
1.6.2.7 Wound related staff labor assessment (optional per sponsor 
instruction) 
 
 
 
1.6.3 
Treatment Phase. (Weeks 1-16): The following treatments and assessments are 
performed during the treatment phase weeks 1-16. During the treatment phase there 
are 2 types of visits: 1. RD1 Change Assessment Visit   2. RD1 Change Visit (performed 
immediately after Change Assessment Visit).  
 
1.6.3.1 
RD1 change assessment visit procedures every 7 days (±3 days): 
 
1.6.3.1.1 
RD1 change will be assessed by investigator  
1.6.3.1.2 
Wound/ blood related adverse event assessment  
1.6.3.1.3 
Assess offloading compliance when applicable. 
1.6.3.1.4 
Assess moisture control when applicable. 
1.6.3.1.5 
Ulcer and blood related concomitant medication review. 
1.6.3.1.6 
Photo the RD1 on the ulcer. 
1.6.3.1.7 
Assessment of the edges of the wound to assess infection. 
1.6.3.1.8 
Assessment of the adherence of the RD1 to the wound. 
 
 
1.6.3.2 
RD1 re-application visit procedures (occurs if investigator decides 
to change RD1, should occur immediately after RD1 change 
assessment visit): 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 12 of 45 
Clinical Protocol  - RD004 Confidential 
 
1.6.3.2.1 
Investigator subjective wound pain assessment pre RD1 
removal 
1.6.3.2.2 
Removal of old RD1 
1.6.3.2.3 
Photography after RD1 removal, before cleansing and 
debridement.  
1.6.3.2.4 
Wound measurement by photography. Two measurements- 
before and after cleansing and debridement.  
1.6.3.2.5 
Wound depth measurement by accepted method. Unit of   
measurement is millimeters. Two measurements- before and 
after cleansing and debridement  
1.6.3.2.6 
Wound assessment. 
1.6.3.2.7 
Ulcer cleansing.  
1.6.3.2.8 
Ulcer debridement as needed.  
1.6.3.2.9 
Assess wound infection. 
1.6.3.2.10 Application Regimen: as per the investigators Brochure. Up to 
3 RD1 dressings can be applied on each wound on each visit, 
according to wound size and investigator decision of subject 
health.  The RD1 will be removed or applied only by the 
research staff. 
1.6.3.2.11 Assessment of wound closure  
1.6.3.2.12 Wound related staff labor (optional per sponsor instruction) 
1.6.3.2.13 RD1 clot residues sent to analysis  
 
1.6.3.3 
Wound healing confirmatory visit. Will be performed to assess 
durability of wound closure. Performed at the earlier of the 2 
options: 1. before discharge from SNF. 2. Two weeks after 
complete healing. For wounds that have healed during the 16 
weeks of active treatment.  
 
1.6.3.3.1 
Wound size measurement by photography. 
1.6.3.3.2 
Wound depth measurement by accepted method. Unit of   
measurement is millimeters 
1.6.3.3.3 
Investigator assessment of healing  
1.6.3.3.4 
Physical examination 
1.6.3.3.5 
Adverse event assessment. 
1.6.3.3.6 
Assess offloading compliance. 
1.6.3.3.7 
Concomitant medication review. 
1.6.3.3.8 
Laboratory: complete blood count, PT, PTT, and HbA1c 
1.6.3.3.9 
Offloading (for up to 2 weeks after wound healing, when 
applicable 
1.6.3.3.10 Investigator subjective wound pain assessment   
1.6.3.3.11 Wound related staff labor during the whole RD1 treatment 
period (optional per sponsor instruction) 
1.6.3.3.12 Wound treatment cost during the whole RD1 treatment period 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 13 of 45 
Clinical Protocol  - RD004 Confidential 
1.6.3.4 
End Of Study/ Early Termination Visit:  At the end of week 16, for 
wounds that have not healed during the 16 weeks of active 
treatment or for early termination from the study, perform: 
 
1.6.3.4.1 
Investigator subjective wound pain assessment pre RD1 
removal 
1.6.3.4.2 
Removal of old RD1 
1.6.3.4.3 
Wound size measurement by photography. Two 
measurements- before and after cleansing and debridement  
1.6.3.4.4 
Wound depth measurement by accepted method. Unit of   
measurement is millimeters. Two measurements- before and 
after cleansing and debridement. 
1.6.3.4.5 
Investigator assessment of healing  
1.6.3.4.6 
Physical examination. 
1.6.3.4.7 
Adverse event assessment. 
1.6.3.4.8 
Assess offloading compliance. 
1.6.3.4.9 
Ulcer and blood related concomitant medication review. 
1.6.3.4.10 Laboratory: complete blood count, PT, PTT, and HbA1c 
1.6.3.4.11 Wound related staff labor during the whole RD1 treatment 
period (optional per sponsor instruction) 
1.6.3.4.12 Wound treatment cost during the whole RD1 treatment period 
(optional per sponsor instruction)  
2. 
SELECTION CRITERIA 
 
All of the study’s inclusion and exclusion criteria must be met by Day 0 (first visit) for the 
subject to be eligible for the treatment phase of the study. 
 
2.1. Inclusion Criteria 
 
2.1.1 
Subject is ≥18 years of age  
2.1.2 
Patient with a wound deemed suitable for treatment with RD1 
2.1.3 
Prior to inclusion of an ulcer in the study, each wound will be reviewed for 
eligibility by an independent assessor using a central online review process that 
includes images of the ulcer. 
2.1.4 
Ulcer free of clinical signs of infection. (Subjects with wound infection at the 
screening visit may be treated and re-screened for participation in the study after 
eradication of the infection).   
2.1.5 
Post-debridement, ulcer free of necrotic tissue. 
2.1.6 
For foot ulcers, Subject has adequate vascular perfusion of the affected limb, as 
defined by Ankle-Brachial Index (ABI) ≥ 0.65 and ≤ 1.2 
2.1.7 
HbA1c ≤ 12.0% (diabetic patients)  
2.1.8 
Subject or legal authorized representative must be willing to comply with the 
protocol including having blood drawn to create the RD1. 
2.1.9 
Female subjects who are capable of conceiving must use an acceptable form of 
contraception in order to participate in the study (acceptable forms of 
contraception include condoms for males and contraceptive pills or IUDs for 
women). 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 14 of 45 
Clinical Protocol  - RD004 Confidential 
 
2.2. Exclusion Criteria 
 
2.1.10 Presence of active underlying osteomyelitis. 
2.1.11 Patient with a proven sepsis established by a blood culture in the past 2 weeks, 
or confirmed active infection likely to interfere with trial, such as urine tract 
infection 
2.1.12 Known malignancy in the reference wound bed or margins of the wound 
2.1.13 Exposure of blood vessels or organs at the base of the reference wound 
2.1.14 History of alcohol or substance abuse, within the previous 2 months 
2.1.15 Subject has participated in another clinical trial involving a device or a 
systemically administered investigational study drug or treatment within 30 days 
of day 0 visit.  
2.1.16 Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive 
a medication or treatment which, in the opinion of the Investigator, is known to 
interfere with, or affect the rate and quality of, wound healing (e.g., systemic 
steroids (more than 10mg per day), immunosuppressive therapy, autoimmune 
disease therapy, cytostatic therapy within the past 12 months, , radiation therapy 
to the ulcer area, vascular surgery, angioplasty or thrombolysis). 
2.1.17 Subject has been treated with wound dressings that include growth factors, 
engineered tissues or skin substitutes (e.g., Regranex®, Dermagraft®, Apligraf®, 
GraftJacket®, OASIS®, Primatrix®, Matristem®, etc.) within 30 days of 
randomization or is scheduled to receive during the study. 
2.1.18 Subject has been treated with hyperbaric oxygen within 5 days of screening or is 
scheduled to receive during the study. 
2.1.19 Wound on a patient who has a life expectancy of less than 6 months. 
2.1.20 Cannot withdraw blood in the required amount technically. 
2.1.21 Known coagulation problems, abnormal thrombocytes level or if heparin is given 
intravenously. Patients who are taking orally Coumadin, Aspirin, or Plavix 
(clopidogrel) will not be excluded. 
2.1.22 Hemoglobin anemia (< 9 g/dL). 
2.1.23 Subject has an infectious disease, such as Acquired Immune Deficiency Disease 
(AIDS) or HIV, Hepatitis C, Hepatitis B, Human T-lymphotropic virus or Syphilis 
2.1.24 Women who are pregnant or currently breast feeding. 
 
 
2.3. Investigator and Site Selection 
      
2.3.1 
Investigators 
 
Study investigator, will be instrumental in choosing the principal and co-
investigators for the trial.  
 
2.3.2 
Sites Selection 
 
All of the sites will have had training in Good Clinical Practices (GCP) with National 
Institutes of Health certification in the ethical treatment of human subjects.  
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 15 of 45 
Clinical Protocol  - RD004 Confidential 
3. 
DIAGNOSTIC EVALUATIONS 
 
3.1. Laboratory Tests 
 
HbA1c 
Complete blood count  
Coagulation tests – PT and PTT 
 
 
4. 
STOPPING RULES 
 
4.1. Individuals 
 
4.1.1 
Infection 
An infection that cannot be controlled or interferes with treatment in such a way 
that a treatment failure is likely to occur. 
 
If cellulitis or local wound infection occurs, the Investigator may interrupt 
treatment in order to address this adverse event. The Investigator will treat 
cellulitis or local wound infection in accordance with his clinical judgment. 
Systemic antibiotic therapy is permitted; however, topical antimicrobials are not 
permitted in combination with RD1. Investigator may interrupt treatment in 
order to apply topical antimicrobials and resume treatment later (in the time 
frame of 16 weeks only) 
 
4.1.2 
Venipuncture 
Inability to complete a successful venipuncture resulting in complete loss of 
venous access. 
 
4.1.3 
Ulcer Deterioration 
Ulcer deterioration, determined by physician discretion. 
 
 
 
4.1.4 
Health Deterioration 
Any health deterioration or acute situation requiring hospitalization or likely to interfere 
with treatment and resulting in treatment failure. 
 
4.1.5 
Necrotic tissue: 
Appearance of substantial necrotic tissue.  
 
 
 
4.3. Study 
 
4.2.1 ≥ 25% of ulcers have deteriorated (Ulcer deterioration is determined by physician 
discretion  
4.2.2   ≥ 50% of ulcers have been infected. 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 16 of 45 
Clinical Protocol  - RD004 Confidential 
 
4.2.3   ≥ 25% of patients have dropped out because of problems with venipuncture. 
 
 
 
 
 
5. 
LONG TERM FOLLOW-UP  
 
5.1. General 
Following the 16-week study the subjects will be treated according to standard wound care. 
Subjects are kept in a database allowing follow-up studies to be conducted. Additional studies 
would only be performed with Ethics Committee approval and patient consent. 
 
 
6. 
MISSED VISITS 
 
If a subject misses a visit, the site is to make every effort to have the subject return as soon as 
possible to make-up the visit. Once the subject is seen, he/she is to return to his/her original visit 
schedule.   
 
Patients who miss more than 2 two consecutive visits during the treatment phase will be withdrawn.  
 
7. 
ADVERSE EVENTS 
 
The NCI CTCAEv4 scale will be used to grade adverse events/serious adverse events.  
 
 
7.1. Serious Adverse Events 
 
Serious Adverse events (SAE) are defined as any adverse change in the subject’s medical 
condition that meets any of the following criteria: results in death; is life-threatening; requires 
inpatient hospitalization or prolongation of existing hospitalization; results in persistent or 
significant disability/incapacity (grades 3-5 using NCI CTCAEv4 scale). 
 
 
Any serious adverse event that occurs during the subject’s participation in the study, even 
though it may not be considered related to the study device by the Principal Investigator, must 
be reported on the case report forms. If an SAE is thought to be related to the device, it must 
also be catalogued under device-related adverse events. 
 
SAEs are reported to the Institutional Review Board (IRB)/Ethics committee and the sponsor 
within 24 hours of recognition by the Principal Investigator.  
 Subjects who develop serious adverse effects should be followed until the event or effect 
resolves or stabilizes.  
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 17 of 45 
Clinical Protocol  - RD004 Confidential 
SAEs will be determined at each visit or whenever the site investigator is notified of an AE and 
determines it to be an SAE, and then recorded. The following information regarding SAEs will 
be collected: 
• 
Description of the event 
• 
Onset date 
• 
Time of onset 
• 
End date 
• 
End Time 
• 
Relationship to study device (e.g., yes, no, likely, unlikely) 
• 
Action taken 
• 
Outcome. 
 
7.2. Device-related Adverse Events 
 
Device-related Adverse Effects (DRAEs) are previously recognized or unrecognized adverse 
events directly related to the use of the RD1. These DRAEs will be reported to the IRB/EC and 
sponsor within 24 hours of the initial discovery of the event. They are also captured in the 
case report forms. A DRAE that is also determined to be an SAE will also be reported 
separately under SAE protocol. 
 
Subjects who develop DRAEs should be followed until the event or effect resolves or stabilizes.  
 
All DRAEs will be collected at each visit and recorded. The following information regarding 
AEs will be collected: 
• 
Description of the event 
• 
Onset date 
• 
Time of onset 
• 
End date 
• 
End time 
• 
Severity 
• 
Categorization of event in relation to study device (Possible, Probable, Definite; 
Unrelated/Unlikely categories should be moved to the SAE/AE list). 
• 
SAE (Y/N) 
• 
Action taken 
• 
Outcome. 
 
Examples of incidents that might be DRAEs include, but are not limited to: 
• 
Complications related to venipuncture but not including lack of venous access  
• 
Infections appearing within 2-4 days of device application. 
• 
Bleeding at the wound site that is not related to any debridement 
• 
Any allergic reactions 
• 
High pain related to product application or removal 
 
7.3. Adverse Events 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 18 of 45 
Clinical Protocol  - RD004 Confidential 
An adverse event (AE) is defined as any adverse change in the subject's medical condition 
including any deterioration, or exacerbation of a pre-existing medical condition that is 
observed by the Investigator or reported by the subject.  
 
All AEs will be collected at each visit and recorded. The following information regarding AEs 
will be collected: 
• 
Description of the event 
• 
Onset date 
• 
Time of onset 
• 
End date 
• 
End time 
• 
Severity 
• 
Action taken 
• 
Outcome. 
 
Examples of anticipated AEs include, but are not limited to: 
• 
Infection not related to device application 
• 
Increase in stage of wound 
• 
Sudden increase in ulcer area or depth  
• 
Peripheral edema or localized swelling 
• 
New ulcer 
• 
Systemic fever 
 
7.4. Subject Referral to another Facility 
 
In case a patient is referred to another facility during the course of the study treatment, due 
to and adverse event, RD1 must be removed prior to subject referral and study treatment 
should be stopped. In some cases, with sponsor approval, study treatment could be resumed 
following subject's return to the SNF.  
 
8. 
PREMATURE WITHDRAWAL OF SUBJECTS 
 
Subjects have the right to withdraw from the study at any time for any reason. The investigator also 
has the right to withdraw a subject from the study, if he/she seems it to be in the subject’s best 
interest. It is recognized that an excessive rate of withdrawals may render the study uninterrupted 
and, therefore, it is desirable to avoid unnecessary withdrawals.  
 
While lack of venous access is not anticipated as a major problem, a subject will be withdrawn from 
the trial if the investigator cannot find venous access during the treatment study visits (Visits 1-16). 
 
Noncompliance with study treatment/ offloading in a manner that interrupt treatment and delay 
healing, according to principal investigator judgment   
 
 
9. 
LOST TO FOLLOW-UP 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 19 of 45 
Clinical Protocol  - RD004 Confidential 
Subjects who are lost to follow-up will be included in the primary safety analysis but only patients 
who complete the study will be included in the secondary objectives analysis; where wound area 
data are missing, imputation using LOCF (last observation carried forward) will be used. 
 
 
10. SUBJECT COMPLIANCE 
 
It is essential that patients comply with the protocol. The Principal Investigator should make every 
effort to ensure patient compliance.  
 
 
11. STUDY MONITORING 
 
  
11.1. Study Records/Source Document Inspection 
  
 
The data for subjects will collected on case report forms (CRFs) and kept in a secure location 
in accordance with HIPAA regulations. The site investigator will allow the research team 
(nurses, data managers etc.), representatives of the sponsor, its monitoring team, the local 
IRB/EC, and other governmental regulatory agencies to monitor/audit/inspect all study 
records, CRFs, IRB/EC/IEC records, and corresponding portions of the site investigator’s office 
and/or hospital medical records at regular intervals throughout the study. These 
monitoring/audits/inspections are conducted to verify adherence to the protocol, integrity of 
the data being captured on the CRFs, and compliance with applicable regulations. The sponsor 
requires that subjects’ medical records will be maintained in a confidential manner. Study 
reports will not identify subjects by name or other identifiers. 
 
11.2. Monitors 
Each study site will be monitored by a qualified representative of the sponsor or any qualified 
monitor delegated to do so, on behalf of the sponsor. The monitor will scrutinize study data 
and conduct at regular intervals throughout the course of the study according to a pre-defined 
monitoring plan. On-site monitoring of the site investigator’s facilities aids in ensuring 
compliance with the protocol.   
 
Any deficiency noted during the monitoring visits will be discussed with the site investigator 
and corrective actions to be taken agreed upon. Should the sponsor determine at any time 
during the study that the site investigator is not in regulatory and/or protocol compliance, 
measures necessary to establish compliance will be implemented. If compliance cannot be 
maintained, the sponsor will suspend or terminate the study at this site. 
 
11.3. Monitoring Plan 
 
11.3.1 Pre-study visit 
1. Assess the site’s infrastructure (staff and facility) for the capability to 
conduct the study. 
2. Evaluate Investigator and staff member’s experience, qualifications, and 
capabilities; signed and dated CVs. 
3. Financial disclosure information. 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 20 of 45 
Clinical Protocol  - RD004 Confidential 
 
The sponsor may waive the pre-study visit in certain sites based on previous 
knowledge or experience with the site or personnel, or other reasons as deemed 
acceptable. 
 
11.3.2 Study initiation visit 
Orient the site investigator’s staff involved in the study on: 
1. Protocol content and procedures  
2. CRF and fill-in process, including queries resolution process 
3. GCP and other regulatory requirements 
4. Informed consent form and process 
5. AE, SAE, DRAE, safety reporting 
6. IRB/EC 
7. Investigational product accountability 
8. Subject information: subject’s identification log, subject pre-screening 
and screening logs, subject enrollment log, and subject study visit log 
9. Study monitoring 
10. Investigator’s site file (ISF) 
11. Report of AEs back from the sponsor to the sites (expedited safety 
reports) 
12. Expectations from the site regarding data collection and timelines 
       
The sponsor may choose to perform a regional investigator meeting instead of the 
initiation visits at each site. 
 
11.3.3 Regular monitoring visit 
1. Check on the progress of the study  
2. Protocol and GCP compliance 
3. Informed consent form and process 
4. CRF completion, correction, source data verification 
5. AE, SAE, DRAE, safety reporting 
6. Investigational product  
7. Investigator’s study file. 
 
(Detailed monitoring schedule to be provided at study initiation.) 
 
11.3.4. Intermediate and final study visit; close out monitoring visit 
Ensure Investigator understands the ongoing responsibilities 
1. Record archival practices for source documents and CRFs after 
completion of the study—up to 15 years. 
2. Follow-up of ongoing DRAEs—up to 30 days after completion of the study 
and of SAEs—until resolution. 
3. Notify the sponsor in the event of Health Authority inspection. 
4. Finalizing all "open" issues and complete source data verification (SDV). 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 21 of 45 
Clinical Protocol  - RD004 Confidential 
12. RECORDS HANDLING AND KEEPING 
 
 
 
12.1. Source Documents 
 
Source documents are the initial documents in which subject data are recorded. This includes, 
but is not limited to, original subject files, hospital records, and original recordings/tracings 
from automated instruments, etc. 
 
The sponsor allows using dedicated work sheets to serve as source documents to collect the 
available source data, on top of all other applicable source documents in the site.  
 
All information captured on the CRF should be accurately supported by the source documents 
unless specifically approved and documented by Sponsor. For example, each subject’s source 
documents should include (but not be limited to): 
• 
Documenting the  informed consent process  
• 
Subject full name and identification 
• 
Date of each study-required visit with a description of the visit and the results of each 
procedure that was performed 
• 
A full and comprehensive anamnesis that will cover subject's medical history, current 
disease, etc. 
• 
All concomitant procedures and medications for the screening eligibility purposes and 
regular visits 
 
Any additional information relevant to the study should be included in the subject’s source 
documents. In particular, any deviations from the study protocol or procedures should be 
recorded in the source documents, if noted. For example, if study-required procedures or 
visits are not completed or are completed outside the time frame specified in the protocol, 
the reasons for the departure should be explained in the source documents, or mentioned 
whether it was waived by the sponsor in advance. The investigator must maintain all study 
documentation at least 2 years after the last approval of marketing application and until there 
are no pending or contemplated marketing applications, or at least 2 years have elapsed since 
the formal discontinuation of clinical development of the investigational product. These 
documents should be retained for a longer period, however, if required by the applicable 
regulatory requirements or by an agreement with the sponsor. The sponsor should inform 
the investigator in writing when the trial-related records are no longer needed.  
 
All study personnel will receive training in protecting the confidentiality of study participants 
and their health information. Study personnel will be asked to provide written verification of 
their receipt of the training. Study data will be coded with a study specific code and will not 
contain participant names. Informed consent forms and other documents that include names 
or linkages between study numbers and names will be kept in a secure locked manner with 
limited access. All databases will be password protected to limit unauthorized access to study 
data. 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 22 of 45 
Clinical Protocol  - RD004 Confidential 
12.2. Data Collection Method 
 
Data from the subject’s permanent medical records (see source documentation section) will 
be recorded on CRFs. These CRFs will be used to transmit the information collected in the 
performance of this study to the clinical database either manually or by electronically.  
 
All source data must be typewritten or filled out in ballpoint pens, accurately and promptly 
following each visit. The corresponding CRF should be completed so that no fields are left 
blank. CRFs entries corrections will be made only by crossing out (single line) incorrect data 
and writing in the revisions. All corrections must be initialed and dated by the individual 
performing/recording them. If the reason for the change is not obvious, an explanation will 
be recorded. Blacking out or using correction fluid or an eraser is not allowed to eliminate 
data. The investigator must review the CRFs for completeness and accuracy and must 
sign/date the forms where indicated. Signature stamps or substitutes are not acceptable. The 
investigator will retain originals of all source documents, subject consent forms, and study 
data as a permanent record. 
 
Each set of CRFs copy should be reviewed for accuracy and completion (signatures, dates, 
adverse events, device-related adverse events, serious adverse events, protocol departures) 
and maintained in the investigator’s study site. 
 
All original data, both paper forms and electronic, will be kept in a secure place with limited 
access; these will be kept in secure locked cupboards at the site. Electronic files will be 
password protected and kept on a study computer or server to which only the study 
coordinator, personnel, and PIs will have access.  
 
 
13. DATA ANALYSIS 
 
13.1. Study Population and Sample size 
13.1.1 The safety population will be all subjects who receive at least one RD1 treatment. 
13.1.2 The intent-to-treat population (ITT) will be all subjects who complete the study. 
13.1.3 Sample size is initially set as 60 but enrollment will be increased if necessary to 
compensate for drop-outs so that 60 patients complete the trial. 
 
13.2. Statistical Analyses 
 
Please refer to the SAP (statistical analysis plan) for full details. 
 
 
 
13.2.1. 
Primary Endpoint 
 
Efficacy- The performance of RD1 in terms of wound progress towards closure in 
wounds deemed suitable for treatment with RD1 (ITT population)  
 
13.2.2. 
Secondary Endpoints 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 23 of 45 
Clinical Protocol  - RD004 Confidential 
 
• 
Safety - Determine complication rates for all adverse events compromising serious 
adverse events, adverse events (AEs), and device-related adverse events (DRAEs); 
AEs include any lack of venous access events (ITT and Safety Population) 
• 
Efficacy - Assess the incidence of complete wound closure at 16 weeks for wounds 
treated with RD1 (defined as skin re-epithelialization without drainage or dressing 
requirements) (ITT population). 
• 
Efficacy - Assess the wound Percent Area Reduction (PAR) (ITT population) 
• 
Efficacy- Assess the optimal duration between applications of RD1 per wound 
parameter  (ITT population) 
• 
Efficacy- Assess the need of design and procedure improvements of the RD1 for 
specialized nursing facilities (SNF) (ITT population) 
• 
Sub Group Analysis – asses the safety and efficacy per wound etiology (subgroup of 
ITT population)  
• 
Asses the cost of RD1 procedure in SNF compared to cost of treatment before RD1 
(ITT population) 
• 
Assess wound pain compared to wound pain during treatment before RD1 (ITT 
population) 
• 
Assess medical staff wound related weekly labor of wound treatment before and 
during RD1. (ITT population) 
 
14.  REGULATORY OBLIGATIONS 
 
 
14.1 Sponsor’s Obligations 
 
The sponsor will assume the following responsibilities: 
1. Provide the investigator with the necessary information—protocol and device user's 
manual or instructions for use (also incorporated into the Investigator Brochure). 
2. Inform the Investigator of all new information that may affect his/her decision of 
whether to continue participation in the study. 
3. Provide supplies for the investigation. 
 
The sponsor will maintain the following records: 
1. A signed protocol and CRF 
2. All correspondence that relates to the clinical trial 
3. Signed investigator agreements 
4. Records of device shipment and disposal (shipping receipts, material 
destruction records, etc.) 
5. Other records as required by the Health Authority. 
 
14.2 Investigator’s Obligations 
 
Clinical research studies are subject to the regulations of the regulatory authority of the 
country. Upon signing the protocol, the investigator agrees to assume the following 
responsibilities and to keep the required records for a period of 2 years after the last approval 
of marketing application and until there are no pending or contemplated marketing 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 24 of 45 
Clinical Protocol  - RD004 Confidential 
applications, or at least 2 years have elapsed since the formal discontinuation of clinical 
development of the investigational product, and to file the required reports in a timely 
manner: 
1. Conduct the investigation in compliance with the protocol. Changes to the protocol 
may only be made after approval by the investigation team and the Ethical Committee 
(IRB/EC), or when necessary to protect the safety, rights, or welfare of a subject. 
2. Personally conduct or supervise the investigation. 
3. Read and understand the information in the Protocol and Investigator Brochure. 
4. Be aware of the potential risks and side effects of the investigational device. 
5. Ensure that all associates, colleagues, and employees assisting in the conduct of the 
study are informed of their obligations. 
6. Inform all subjects that the device is being used for investigational purposes and 
ensure that the requirements related to obtaining the informed consent are met. 
7. Dispose of or return remaining supplies as directed by the sponsor. 
Maintain the following records (for the period of time as specified above): 
1. Signed copy of the protocol 
2. Signed consent forms 
3. All correspondence relating to the clinical trial 
4. Case Report Forms. 
 
File the following reports: 
1. Serious unexpected adverse DRAE reports received by the sponsor. 
2. Regular SAE reports produced by the PI. 
3. Deviations made from the protocol for emergency use, must be reported to the 
sponsor as soon as possible, but no later than five working days after occurrence. 
 
15. STUDY COMPLETION 
 
The PI will complete and report the study in satisfactory compliance with the protocol. 
It is agreed that, for any reasonable cause, either the PI or the Sponsor, may terminate this study, 
provided a written notice is submitted at a reasonable time in advance of intended termination. 
If the study is terminated for safety reasons, the investigator will be notified immediately by 
telephone, followed by written instructions for study termination notification of the IRB/EC. 
 
16. PROTOCOL DEVIATIONS AND EXCEPTIONS 
 
The investigator should not implement any deviation from or changes to the protocol without 
agreement of the sponsor, in some cases the IRB/EC should be notified and approve the deviation 
(if safety to the subject or if the scientific soundness of the study is involved), except where 
necessary to eliminate an immediate hazard(s) to trial subjects. 
 
The investigator should document and explain any deviation from the approved protocol and file 
waivers received from the sponsor, if applicable. The reasons, and if appropriate, the proposed 
protocol amendments should be documented in the CRF and submitted to: 
1.  The sponsor for agreement 
2.  IRB/EC 
3.  The regulatory authority. 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 25 of 45 
Clinical Protocol  - RD004 Confidential 
 
 
17. ETHICAL STUDY CONDUCT 
 
This study will be conducted in compliance with the protocol after approval of the IRB/EC, and 
according to Good Clinical Practice (GCP) and international standards, such as ISO 14155. No 
deviation from the protocol, after the investigation team approval will be implemented without 
the prior review and approval of the IRB except where it may be necessary to eliminate an 
immediate hazard to a research subject. In such case, the deviation will be reported to the IRB 
and to the sponsor as soon as possible. 
 
A copy of the protocol, Informed Consent Form (ICF), and advertising material must be submitted 
to the IRB/EC. Written approval of the protocol ICF and advertising material must be obtained 
prior to subject enrollment by the IRB/EC. 
 
 
 
 
18. CONFIDENTIALITY/PUBLICATION OF STUDY RESULTS 
 
This clinical study is confidential and should not be discussed with individuals outside the study. 
Additionally, the information in this document and in the study may contain secrets and 
commercially sensitive information that is confidential and may not be disclosed unless such 
disclosure is required by federal or state law or regulations. Subject to the foregoing, this 
information may be disclosed only to those persons involved in the study that have a need to 
know, but all such persons must be instructed not to further disseminate this information to 
others. 
 
For publication rules please see the agreed upon signed study contract with the study center. 
 
The data may be used now and in the future for presentation or publication at the investigator and/or 
sponsor’s discretion or for submission to governmental regulatory agencies. All reports and 
communications relating to subjects in the study will identify each subject only by the subject’s initials 
and by the subject’s study number. 
 
 
 
 
 
 
 
 
 
 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 26 of 45 
Clinical Protocol  - RD004 Confidential 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 1 
INFORMED CONSENT FORM 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 27 of 45 
Clinical Protocol  - RD004 Confidential 
APPENDIX 2 
RD1™ APPLICATION PROTOCOL 
 
RD1 Preparation 
 
The patient phlebotomy kit includes the following products: 
• 
1 Sterile syringes of 2.5 mL; 
• 
A sterile syringe of 20 mL; 
• 
A CPDA1 blood collection bag (as a source of CPDA1 anti-coagulant) or two  FDA cleared vacuum 
tubes with ACDA Solution  
• 
A sterile blood collection set with a 21G needle 
 
The coagulation initiator and accelerator kit includes the following items: 
• 
A 10 mL sterile ampoule of calcium gluconate (manufactured by APP Pharmaceuticals); 
• 
35 mg kaolin powder (manufactured by Charles B. Chrystal Co., Inc.), sterilized in a vial; and 
• 
A 10 mL syringe. 
 
The clotting trays consist of 3 sizes of sterile biocompatible plastic boxes, each containing sterile 
cotton medical gauze.  The trays are separately packed and marked small, medium or large, with 
the RD1 diameter written on them. The sizes of the clotting tray (small, medium or large) to be 
used to create RD1 patches for different wound sizes are also presented in Table 1 below. 
 
 
 
Table 1. Clotting trays. 
Clotting tray 
Picture 
RD1 diameter 
Small 
 
2.8 cm 
Medium  
 
3.7  cm 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 28 of 45 
Clinical Protocol  - RD004 Confidential 
Large 
 
 
4.5  cm 
 
Follow the instructions below to use the RD1 System: 
 
1. Measure the ulcer maximal length. 
2. Open the sterile RD1 kit, and spread its contents on a flat, sterile surface near the patient.   
3. Select the appropriate clotting tray size based on the measured maximal wound size, and place 
it in the empty kit tray.  
4. Make sure that the RD1 tray cover is firmly attached to the tray from all sides so blood will not 
leak. 
5. Make sure the RD1 tray is horizontal. 
6. Use the materials titration table and the steps described below to create the RD1 whole blood 
clot gel: 
 
 
 
 
Table 2. Materials titration table. 
 
RD1 
Clotting 
Tray 
Procedure 
Syringe 
CPDA1  
Anti-
coagulant 
Blood 
Amount 
Coagulants 
Mixture  
6 mL Calcium 
in Kaolin Vial 
Final 
Volume 
in 
syringe 
Amount to 
be injected 
to RD1 
clotting tray 
RD1  
Circular 
Area 
Covered 
Small 
20 mL 
1 mL 
10 mL 
2 mL 
13 mL 
7 mL 
8.8 cm2 
Medium  
20 mL 
1 mL 
10 mL 
2 mL 
13 mL 
10 mL 
11.6 cm2 
Large 
20 mL  
1 mL 
10 mL 
2 mL 
13 mL 
13 mL 
16 cm2 
 
7. Preparing the CPDA1 in a syringe or the ACDA tubes 
In case of CPDA1 syringe: 
a. Insert the needle of the 2.5 mL syringe into the bag containing CPDA1  
b. Withdraw CPDA1 in the amount specified in Table 2. 
c. Inject the CPDA1 from the 2.5 mL syringe into the 20 mL procedure syringe. 
d. Cover the procedure syringe with a covered needle.  
        In case of ACDA tube 
e. Extract the tube from the kit 
 
8. Preparing coagulants mixture (6 mL calcium gluconate in the kaolin vial): 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 29 of 45 
Clinical Protocol  - RD004 Confidential 
a. Withdraw 6 mL calcium gluconate from its ampoule, using the 10 mL syringe with a 
needle. 
b. Inject the 6 mL calcium gluconate into the sterile sealed kaolin powder glass vial through 
its rubber plug, and close the needle cover. 
c. Shake the kaolin and calcium gluconate mixture well until a uniform suspension is 
obtained. 
d. Remove the needle cover and withdrawal the calcium + kaolin suspension into the 10 
mL syringe, according to the amount in Table 2.  
 
9. Phlebotomy: 
 
a. Change the needle to a new one on the 20 mL syringe containing the CPDA1. 
b. Wrap tourniquet proximal to the puncture site. 
c. Cleanse venipuncture site with alcohol prep.   
d. Withdraw blood from the patient vain in the appropriate amount, according to Table 2, 
using the blood collection set 21G needle, either with CPDA1 syringe or 2 ACDA 8.5ml 
tubes. 
e. Remove the tourniquet and the needle 
f. Apply pressure to the site with 2” x 2” gauze. Apply a band-aid over the site. 
g. Introduce a small amount of air into the syringe in order to facilitate the mixing of the 
syringe contents. Tilt the syringe gently 3-4 times or tilt the tubes. 
 
Note – Blood withdrawal and handling should be performed according to standard blood 
withdrawal precaution guidelines.    
 
10. In case you used 2 vacuum tubes: draw 12ml of the tube content into the 20ml syringe and 
dispose of the 2 tubes 
11. Inject the calcium + kaolin suspension from its syringe into the 20 mL syringe containing the 
blood. 
12. Draw some air into the syringe in order to facilitate the mixing of the syringe contents. Tilt the 
syringe gently 3-4 times. 
13. Remove the needle to prepare for injecting the material into the RD1 clotting tray, which must 
be done immediately. 
14. Insert the syringe tip into the upper hole in the RD1 tray. 
15. Inject the coagulating blood into the RD1 tray using moderate pressure, as shown below. 
 
 
 
 
 
 
 
 
 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 30 of 45 
Clinical Protocol  - RD004 Confidential 
 
Figure 1. Immediate injection into the RD1 tray. 
 
16. Wait 12 minutes for complete coagulation to occur. 
17. Use one hand to affix the pad rim and clotting tray base while the other hand lifts the lid of the 
tray. 
For the medium and small clotting trays: Use one hand to hold the clotting tray while the other 
hand affixes the pad rim on the lid, and screw out both gauze and lid (see Figure 2). 
 
 
 
 
 
 
 
 
 
 
Figure 2. Opening the clotting trays. 
Handling and placing the RD1:    
18. Wear sterile gloves. 
19. Gently remove the RD1 from the clotting tray by holding it from its rim. Use both hands.       
20. Place the RD1 over the wound with the embedded pad facing upwards (distal). 
21. The RD1 clot gel may be shaped, if needed, by cutting it with sterile scissors. Cutting should be 
performed on the surgery tray or while being held in the gloved hand. 
Note: Make sure that the RD1 is large enough to cover the entire wound, covering at least 0.5 cm of 
surrounding skin around wound edges. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Handling the RD1. 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 31 of 45 
Clinical Protocol  - RD004 Confidential 
Affixing the RD1: 
22. Anchor the RD1 to the wound by its rim with Steri-strips.  
23. Place a primary non-adhesive dressing such as Mepitel over the RD1. 
24. Place a secondary absorbent dressing on top.  
 
RD1 Removal (after approx. 7 days): 
25. Wear gloves. 
26. Remove the remaining RD1 by pulling it gently off the wound. 
27. In case of adhesions, wet the RD1 with saline to facilitate gentle removal. 
28. Discard of the remaining RD1 properly. 
 
 
RD1 kit allocation 
RedDress ltd. Will provide the research centers pharmacies/ designated personnel with the RD1 
investigational kit. The pharmacies/ designated personnel will allocate the supply to the 
investigators, in accordance to a pre-defined procedure.  
 
RD1 kit storage conditions 
Store in the original container at a controlled room temperature of 15°C (59°F) – 25°C (77°F).  
Protect from freezing and avoid excessive heat. 
 
 
Shelf Life 
2 Years from date of manufacturing 
Disposal instructions 
Dispose of all blood, tools, and materials according to local requirements.  
 
In the absence of incompatibility studies, this medicinal product must not be mixed with other 
medicinal products. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 32 of 45 
Clinical Protocol  - RD004 Confidential 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 3 
PHOTOGRAPHIC TECHNIQUE 
 
3 Photographs will be taken at every visit: 
1. Before RD1 removal (not relevant for screening visit and day 0 visit) 
2. Before cleansing and debridement (if performed) 
3. After cleansing and debridement- before RD1 application. 
All research staff must undergo training for the use of the specifically designated camera that is used in 
the standard work, including: 
1. Specific photography guidelines as, lightning, distance from ulcer and direction of photography 
2. Performing 2 photos per ulcer 
3. Validating the quality of the photo 
4. Allocating specific name to the photo file 
5. Saving photos 
6. Sharing photos 
7. Measuring the ulcer in the photo 
8. Measuring the depth of the ulcer 
9. Backup of photos 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 33 of 45 
Clinical Protocol  - RD004 Confidential 
APPENDIX 4 
WOUND MEASUREMENT 
 
Wound size measurements will be obtained using digital analysis with acceptable tool, before the use of 
the tool validation data will be assessed and the tool will be cleared for use by sponsor. 
 
Wound depth measurement will be obtained by an accepted method, i.e. Measure distance from deepest 
base of wound bed to level of usual skin surface and at a 90° angle to skin surface using a sterile probe 
and ruler. Unit of   measurement is millimeters.  
 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 34 of 45 
Clinical Protocol  - RD004 Confidential 
APPENDIX 5 
IMAGING CHARTER 
 
The main goal of central imaging/planimetry review is to confirm assessment by an additional assessor 
that a wound has closed (initial assessment, then re-assessment 2 weeks later). Secondary goals include 
confirming each wound eligibility at study entry, review of a wound that has increased ≥ 50% in area or 
increased in grade to confirm whether a patient should be withdrawn, or review at the request of any site 
assessor. 
 
The following steps will occur: 
1. There will be one independent central reviewer who is experienced at wound care. 
2. The reviewer will receive the wound image and data via e-mail  
3. The reviewer will assess whether the wound is closed or not (or other assessment, as requested). 
4. The reviewer will communicate his or her decision to the Medical Monitor. 
5. If there is disagreement between the site assessor and the imaging reviewer, then the Medical Monitor 
will adjudicate using best judgment, and communicate any change in wound status back to the site 
assessor. The Medical Monitor will also have access to wound images and data from patient visit records. 
 
 
 
 
 
 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 35 of 45 
Clinical Protocol  - RD004 Confidential 
APPENDIX 6 
TRAINING AND STANDARDIZATION OF CARE AT CENTERS 
 
 
All study personnel will be trained in the care of ulcers and specific procedures as noted below:  
 
 
Centers will follow debridement techniques according to appendix 8 of this protocol. 
Centers will follow photography techniques according to appendix 3 of this protocol  
Centers will follow infection assessments technique according to appendix 11 of this protocol 
Centers will follow moisture control assessments technique according to appendix 12 of this protocol 
Centers will follow offloading techniques according to appendix 13 of this protocol  
Centers will follow wound grading system according to appendix 9 of this protocol 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 36 of 45 
Clinical Protocol  - RD004 Confidential 
APPENDIX 7 
SCHEDULE OF EVENTS 
 
 
 
PROCEDURES 
SCREENING 
PHASE  (DAY 
0) 
RD1 CHANGE 
ASSESSMENT 
VISIT 
RD1 
RE-
APPLICATION 
VISIT 
HEALING 
CONFIRMATORY 
VISIT 
(if 
applicable) 
END OF STUDY/ 
EARLY 
TERMINATON  
VISIT 
Informed Consent 
X 
  
  
  
  
Inclusion/Exclusion 
X 
  
  
  
  
Medical History 
X 
  
  
  
  
Physical Exam 
X 
 
 
 X 
 X 
Demographics  
X 
 
 
 
 
Ulcer classification and grading 
X 
 
 
 
 
Neuropathic assessment (Foot Ulcers only) 
X 
 
 
 
 
Infection assessment 
X 
X 
X 
X 
X 
Assessment of moisture control 
X 
X 
X 
X 
X 
Vascular 
perfusion 
assessments 
(when 
relevant) 
X 
 
 
 
 
Laboratory tests 
X 
 
 
X 
X 
X-Ray of the study ulcer 
X (only if 
osteomyelit
is 
suspected) 
 
 
 
 
Ulcer and blood related concomitant Meds 
X 
X 
X 
X 
X 
Standard of care therapy 
X 
 
 
 
 
Ulcer cleansing and debridement  
X 
 
X 
 
X 
RD1 change assessment 
 
X 
 
 
 
Apply RD1 
X (day 0 
only) 
 
X  
 
 
Wound photography 
X 
X 
X 
X 
X 
Wound measurement/assessment 
X 
X 
X 
X 
X 
Adverse Event 
X 
X 
X 
X 
X 
Offloading Compliance Assessment 
X 
X 
X 
X 
X 
Pain Assessment  
X 
 
X 
X 
X 
Staff labor assessment 
X 
 
X 
X 
X 
Pre-RD1 wound treatment cost assessment  
X 
(on 
screening) 
 
 
 
 
RD1 procedure cost assessment 
X (on day 0) 
 
 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 37 of 45 
Clinical Protocol  - RD004 Confidential 
 
 
APPENDIX 8 
DEBRIDEMENT 
 
Debridement is an essential technique in the treatment of chronic ulcers. It is important to remove all 
non-viable and necrotic material from the target ulcer prior to enrolling the patient. It is also important 
that that all of the investigators debride the wound in a similar fashion. The study site will be provided 
with a training video and all of the investigators will be trained on the technique. Briefly, the following 
procedures should be followed: 
 
1. The target ulcer and the surrounding skin are prepped with saline solution.  
2. Using clean technique a surgical blade and/or scissors and forceps the skin around the edge of the 
wound is excised. All non-viable and necrotic tissue in the wound bed is removed. 
3. Ideally hemostasis is achieved using direct pressure. Cautery may be employed if necessary, but 
should not be done more than once. 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 38 of 45 
Clinical Protocol  - RD004 Confidential 
 
APPENDIX 9 
ULCER GRADING SYSTEM 
 
Each wound will be classified and graded according to the relevant etiology grading system, as described 
below: 
 
Pressure Ulcers 
 
Pressure Ulcer Stages Revised by NPUAP 
 
Suspected Deep Tissue Injury:  
Purple or maroon localized area of discolored intact skin or blood-filled blister due to damage of 
underlying soft tissue from pressure and/or shear. The area may be preceded by tissue that is painful, 
firm, mushy, boggy, warmer or cooler as compared to adjacent tissue.  
 
Further description:  
Deep tissue injury may be difficult to detect in individuals with dark skin tones. Evolution may include a 
thin blister over a dark wound bed. The wound may further evolve and become covered by thin eschar. 
Evolution may be rapid exposing additional layers of tissue even with optimal treatment.  
 
Stage I:  
Intact skin with non-blanchable redness of a localized area usually over a bony prominence. Darkly 
pigmented skin may not have visible blanching; its color may differ from the surrounding area. 
 
Further description:  
The area may be painful, firm, soft, warmer or cooler as compared to adjacent tissue. Stage I may be 
difficult to detect in individuals with dark skin tones. May indicate "at risk" persons (a heralding sign of 
risk)  
 
Stage II:  
Partial thickness loss of dermis presenting as a shallow open ulcer with a red pink wound bed, without 
slough. May also present as an intact or open/ruptured serum-filled blister.  
 
Further description:  
Presents as a shiny or dry shallow ulcer without slough or bruising.* This stage should not be used to 
describe skin tears, tape burns, perineal dermatitis, maceration or excoriation.  
*Bruising indicates suspected deep tissue injury 
 
Stage III:  
Full thickness tissue loss. Subcutaneous fat may be visible but bone, tendon or muscle are not exposed. 
Slough may be present but does not obscure the depth of tissue loss. May include undermining and 
tunneling.  
 
Further description:  
The depth of a stage III pressure ulcer varies by anatomical location. The bridge of the nose, ear, occiput 
and malleolus do not have subcutaneous tissue and stage III ulcers can be shallow. In contrast, areas of 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 39 of 45 
Clinical Protocol  - RD004 Confidential 
significant adiposity can develop extremely deep stage III pressure ulcers. Bone/tendon is not visible or 
directly palpable. 
 
Stage IV:  
Full thickness tissue loss with exposed bone, tendon or muscle. Slough or eschar may be present on 
some parts of the wound bed. Often include undermining and tunneling. 
 
Further description:  
The depth of a stage IV pressure ulcer varies by anatomical location. The bridge of the nose, ear, occiput 
and malleolus do not have subcutaneous tissue and these ulcers can be shallow. Stage IV ulcers can 
extend into muscle and/or supporting structures (e.g., fascia, tendon or joint capsule) making 
osteomyelitis possible. Exposed bone/tendon is visible or directly palpable. 
 
Unstageable:  
Full thickness tissue loss in which the base of the ulcer is covered by slough (yellow, tan, gray, green or 
brown) and/or eschar (tan, brown or black) in the wound bed. 
 
Further description:  
Until enough slough and/or eschar is removed to expose the base of the wound, the true depth, and 
therefore stage, cannot be determined. Stable (dry, adherent, intact without erythema or fluctuance) 
eschar on the heels serves as "the body's natural (biological) cover" and should not be removed.  
 
For more information, contact npuap.org or 202-521-6789 
 
Copyright: NPUAP 2007 
 
 
Diabetic Foot Ulcers 
Wagner grade 
 
Grade 0- No open lesions; may have deformity or cellulitis 
Grade 1- Superficial diabetic ulcer (partial or full thickness) 
Grade 2- Ulcer extension to ligament, tendon, joint capsule, or deep fascia without abscess or 
osteomyelitis 
Grade 3- Deep ulcer with abscess, osteomyelitis, or joint sepsis 
Grade 4- Gangrene localized to portion of forefoot or heel 
Grade 5- Extensive gangrenous involvement of the entire foot 
 
 
 
 
 
 
 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 40 of 45 
Clinical Protocol  - RD004 Confidential 
APPENDIX 10 
NEUROPATHIC ASSESSMENT 
 
Neuropathic Assessment- foot ulcers only  
Sensory neuropathy will be quantified using the Semmes-Weinstein test to evaluate the 10 locations 
shown in Figure 1. For this trial, the 10 g 5.07 gauge monofilament will be used. The number of sites where 
the subject does not perceive sensation will be recorded in the CRF. 
 
Figure 1. Semmes-Weinstein 10 Point Sensory Neuropathy Screen 
 
 
 
 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 41 of 45 
Clinical Protocol  - RD004 Confidential 
APPENDIX 11 
 INFECTION ASSESSMENT 
 
 
 
Infection of the index wound will be determined by the physician, taking into account the following 
parameters: 
 
 
1. Increased surface area, depth or grade.  
2. Increased periwound margin temperature by more than 3⁰F difference between 2 mirror image sites; 
3. New areas of breakdown or satellite lesions 
4. Presence of swelling or reddened skin in periwound area 
5. Increased wound drainage 
6. Unpleasant, sweet, or sickening odor present.  
7. Excessive bleeding on a wound 
8. Increased pain of the wound  
 
In the case the wound has exposed bone or can be probed to the bone, the patient will be withdrawn 
from the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 42 of 45 
Clinical Protocol  - RD004 Confidential 
 
APPENDIX 12 
MOISTURE CONTROL ASSESSMENT 
 
Assessment of moisture control will be based upon determining whether there is maceration at the skin 
edge. If there is maceration, clinicians will be instructed to examine whether the secondary absorbent 
dressing is appropriate, or whether excessive exudation is taking place. The clinician may also elicit 
discussion with the patient regarding care of the wound. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 43 of 45 
Clinical Protocol  - RD004 Confidential 
APPENDIX 13 
OFFLOADING DEVICE INSTRUCTIONS 
 
 
Offloading will be assessed at each visit and determined whether it is adequate, and whether patient 
compliance is satisfactory. Because there is little evidence to suggest that one type of offloading is 
superior to another, if a pressure-relieving surface is being utilized for a truncal ulcer (such as an 
appropriate overlay or alternating/low-air-loss mattresses for full-thickness ulcers), appropriate footwear 
for a heel ulcer (active offloading walker (boot and/or shoe)), or suitable pressure relief for any other ulcer 
location, then offloading will be regarded as adequate. If this is not the case, the patient will be further 
educated. 
For subjects who do achieve complete closure during the treatment phase, use of the offloading device is 
recommended for at least 2 weeks. 
 
 
 
 
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 44 of 45 
Clinical Protocol  - RD004 Confidential 
APPENDIX 14 
STANDARD CARE 
 
 
 
 
The study center will provide the study ulcer with standard care during screening period, per physician 
discretion  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 45 of 45 
Clinical Protocol  - RD004 Confidential 
APPENDIX 15 
INVESIGATOR SUBJECTIVE ULCER PAIN ASSESSMENT  
 
Investigator will assess the ulcer pain level of the subject, from 0 to 10, based on observation on 
the subject prior to RD1 removal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 46 of 45 
Clinical Protocol  - RD004 Confidential 
APPENDIX 16 
PROCEDURE COST AND STAFF LABOR ASSESSMENTS 
 
 
Staff labor (human resource) and procedure cost data will be gathered during the study including also 
subject and medical staff questionnaires. Specific parameters will be determined after the first 5 subject 
will complete the. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 47 of 45 
Clinical Protocol  - RD004 Confidential 
INVESTIGATOR AGREEMENT FOR TRIAL PROTOCOL  
 
I have read the foregoing protocol RD004, and agree to: 
• 
Conduct the study as outlined herein; 
• 
Maintain the confidentiality of all information received or developed in connection with this 
protocol, and 
• 
Conduct this study in accordance with GCP standards and any other applicable local/state laws 
and regulations; 
• 
Comply with the signed investigators agreement. 
 
 
__________________________________                   __________________________ 
Investigator Signature  
 
 
 
           Date 
 
______________________________________________________________________ 
Investigator name in capital letters 
 
______________________________________________________________________ 
Telephone number 
 
______________________________________________________________________ 
Fax number 
 
______________________________________________________________________ 
Email address 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

        RD004 Rev 1.1, dated 13 August 2018                                             Page 48 of 45 
Clinical Protocol  - RD004 Confidential 
 
 
 
 
 
  
REFERENCES (cited and selected) 
 
References 
1. 
Clayton W Jr, Elasy TA. A review of the pathophysiology, classification, and treatment of foot 
ulcers in diabetic patients. Clin Diabetes 2007;52-8. 
2. 
Wagner FW Jr. The diabetic foot. Orthopedics 1987;10:163-72. 
4. 
Lavery LA, Armstrong DG, Harkless LB. Classification of diabetic foot wounds. J Foot Ankle Surg 
1996;35:528-31. 
5. 
Margolis D, Malay DS, Hoffstad OJ, et al. Incidence of diabetic foot ulcer and lower extremity 
amputation among Medicare beneficiaries, 2006 to 2008. Data Points #2. Rockville, MD: Agency for 
Healthcare Research and Quality. January 2011. AHRQ Publication No. 10(11)-EHC009-1-EF. 
6. 
Driver VR, Fabbi M, Lavery LA, et al. The costs of diabetic foot: the economic case for the limb 
salvage team. J Am Podiatr Med Assoc 2010;100:335-41. 
7. 
Tseng CH. Prevalence and risk factors of diabetic foot problems in Taiwan: a cross-sectional survey 
of non-type 1 diabetic patients from a nationally representative sample. Diabetes Care 2003;26:3351. 
8. 
Qari FA, Akbar D. Diabetic foot: presentation and treatment. Saudi Med J 2000;21:443-446. 
9. 
Dinh T, Veves A. The influence of gender as a risk factor in diabetic foot ulceration. Wounds 
2008;20:127-131. 
10. Carter MJ, Fife CE, Walker D, et al. Estimating the applicability of wound care randomized 
controlled trials to general wound-care populations by estimating the percentage of individuals 
excluded from a typical wound-care population in such trials. Adv Skin Wound Care 2009;22:316-24. 
11. Greer N, Foman N, Dorrian J, et al. Advanced wound care therapies for non-healing diabetic, 
venous, and arterial Ulcers: A systematic review. Washington DC: Department of Veterans Affairs, 
Veterans Health Administration: 2012; VA-ESP Project #09-009. 
12. Game FL, Hinchliffe RJ, Apelqvist J, et al. A systematic review of interventions to enhance the 
healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev 2012;28 Suppl 1:119-41. 
13. Wagner FW. The diabetic foot. Orthopedics 1987; 10:163-172